Head-To-Head Survey: Exactech (EXAC) versus LivaNova (LIVN)

Exactech (NASDAQ: EXAC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.


This table compares Exactech and LivaNova’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exactech 0.18% 7.22% 5.84%
LivaNova 4.63% 9.33% 6.82%

Valuation and Earnings

This table compares Exactech and LivaNova’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Exactech $257.57 million 2.76 $160,000.00 $0.02 2,462.50
LivaNova $1.21 billion 3.31 -$62.78 million $1.17 71.24

Exactech has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Exactech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Exactech has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Exactech and LivaNova, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exactech 0 3 0 0 2.00
LivaNova 1 2 4 0 2.43

Exactech presently has a consensus target price of $49.00, suggesting a potential downside of 0.51%. LivaNova has a consensus target price of $78.17, suggesting a potential downside of 6.22%. Given Exactech’s higher possible upside, research analysts clearly believe Exactech is more favorable than LivaNova.

Insider & Institutional Ownership

61.2% of Exactech shares are owned by institutional investors. Comparatively, 88.5% of LivaNova shares are owned by institutional investors. 28.3% of Exactech shares are owned by insiders. Comparatively, 0.3% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


LivaNova beats Exactech on 9 of the 14 factors compared between the two stocks.

Exactech Company Profile

Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply